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Abstract: The human microbiome is gaining increasing attention in the medical community,
as knowledge on its role not only in health but also in disease development and response to therapies
is expanding. Furthermore, the connection between the microbiota and cancer, especially the link
between the gut microbiota and gastrointestinal tumors, is becoming clearer. The interaction between
the microbiota and the response to chemotherapies and, more recently, to immunotherapy has been
widely studied, and a connection between a peculiar type of microbiota and a better response to these
therapies and a different incidence in toxicities has been hypothesized. As knowledge on the gut
microbiota increases, interest in the residing microbial population in other systems of our body is also
increasing. Consequently, the urinary microbiota is under evaluation for its possible implications
in genitourinary diseases, including cancer. Prostate cancer is the most common cancer in the male
population; thus, research regarding its etiology and possible factors correlated to disease progression
or the response to specific therapies is thriving. This review has the purpose to recollect the current
knowledge on the relationship between the human microbiota and prostate cancer.
Keywords: microbiota; microbiome; prostate cancer; genitourinary cancers
1. Introduction
The multifactorial process of tumorigenesis and the mechanisms promoting cancer progression or
response to therapies are everlasting areas of interest for oncologists. In this scenario, the role of the
human microbiota and microbiome (i.e., the whole gastrointestinal bacterial population and relative
genomes) is gaining attention, as increasing evidence links these commensal bacteria not only to the
maintenance of health but also to the development of multiple diseases, including cancer [1–3].
The human microbiota can be defined as the microorganisms, such as bacteria, archaea, fungi,
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and protozoa that physiologically live in the epithelial barrier surfaces of our body [4]. The microbiome
represents the totality of microbes and their genetic information [5].
The host and its microbiota usually are in symbiotic equilibrium, which, when altered by several
stressors such as environmental factors, dietary changes, or drugs, can lead to a dysbiosis that in turn
can promote many diseases [6].
Knowledge of the composition of the human microbiota is rapidly increasing through 16S
ribosomal RNA or DNA sequencing metagenomics approaches that either provide strong information
about taxonomy, thus simplifying the complexity of bacterial classification, or whole bacterial genome,
unravelling several bacterial functions. Thus, since information on the normal composition and
functions of the microbiota in the gastrointestinal system and the genitourinary system has already
been gained, attention is now focused on the alteration in its composition when specific diseases arise,
including cancer [2].
Furthermore, in the oncologic field a particular interest is in studying the role of the microbiota
connected with specific therapies, including chemotherapy and immunotherapy [7,8].
Among malignancies, prostate cancer is the most frequent in the male population, with 175,000
estimated new cases and about 32,000 estimated deaths in the United States of America in
2019 [9]. The pathogenesis of this type of cancer is mainly linked to its dependence on androgen
hormones. Accordingly, the main treatments of prostate cancer are based on anti-androgen therapies.
The discovery of other pathogenic events, possible risk factors, or the mechanisms behind the eventual
state of resistance to therapies are of great interest.
In this still immature scenario, with increasing interest in the microbiota as a new player in several
human diseases, we present a review of the connections between the microbiota and cancer with
a specific focus on prostate cancer.
2. The Human Microbiota
The role of the microbiota has been gaining more attention as knowledge of its functions
has grown: it is implicated in metabolism, neurological and cognitive functions, hematopoiesis,
inflammation, and immunity [1,10].
The composition of the microbiota varies depending on genetic factors, colonization at time
of birth, type of delivery, host’s lifestyle, exposure to antibiotics or other drugs, dietary factors,
and diseases [11–15].
Moreover, the microbiota composition changes according to the system environment in which it
resides. The intestinal microbiota is mainly composed of five bacterial phyla: Firmicutes, Bacteroidetes,
Actinobacteria, Proteobacteria, and Verrucomicrobia [16–18]. The most represented anaerobes are
Bacteroides, Eubacteria, Bifidobacteria, Clostridia, Peptostreptococci, and Ruminococci [16].
For a long time, the urinary tract was considered to be a sterile environment, but recent
discoveries gained through PCR and 16S ribosomal RNA sequencing technology on urine samples
have proved that it contains a peculiar microbiota [19–21]. The urinary microbiota composition
seems to differ according to gender, as a result of the anatomical structure and hormonal differences
between the sexes, and of age [21]. The genera Lactobacillus and Gardnerella are predominant in the
female microbiota, whereas the male microbiota presents a higher percentage of Corynebacterium,
Staphylococcus, and Streptococcus [22,23].
The microbiota differs from healthy people and patients with different urinary diseases.
Lewis et al. analyzed clean-catch midstream urine of healthy individuals and found Jonquetella,
Parvimonas, Proteiniphilum, and Saccharofermentans to be the more represented genera, with a more
heterogeneous mix of bacterial genera in female samples, which also presented members of the phyla
Actinobacteria and Bacteroidetes, which were absent from the male samples [21]. Willner and colleagues
characterized the bacteria present in 50 patients with acute uncomplicated urinary tract infections using
culture-independent sequence-based methods and reported that the predominant taxa were Escherichia
(Escherichia coli being the most common organism in general), Anaerococcus, Peptoniphilus, Streptococcus,
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Lactobacillus, Staphylococcus, and Pseudomonas [24]. Pearce et al. sequenced urine samples collected
through transurethral catheter from healthy women and women with urgency urinary incontinence
(UUI) [25]. The results showed two different microbiomes between the two cohorts: the patients
with UUI presented a higher representation of nine genera: Actinobaculum, Actinomyces, Aerococcus,
Arthrobacter, Corynebacterium, Gardnerella, Oligella, Staphylococcus, Streptococcus, and a decreased
percentage of Lactobacillus [25].
The role of the urogenital microbiota is under evaluation for its possible implications in urogenital
diseases, both benign, such as urinary tract infections, urinary incontinence, interstitial cystitis, chronic
prostatitis, urolithiasis [19,26,27], and malign, in regards to bladder, prostate, and kidney cancer [28,29].
The host and the microbiota share a complex balanced relationship that can be overthrown in
a state of dysbiosis consequent to environmental changes that alter the microbiome or the host, leading
to promotion of diseases [6]. The homeostasis is based on the integrity of the epithelial barrier colonized
by the microbiota and that protects the host. An alteration in the composition of the microbiota, known
as dysbiosis, can cause a breach of the epithelial barrier and can result in inflammatory bowel diseases,
allergies, metabolic disorders, and cancer [30–33].
The gut microbiota is gaining a relevant role in the tumorigenesis process: increasing evidence
suggests that the intestinal microbiota may have both an anti-tumoral [34–36] and a pro-tumoral
effect [37–40]. The microbiota can influence cancer development and progression because it seems to
be able to modulate inflammation and genomic stability of host cells [6,41].
Recently, an unexpected presence of bacteria within tumor tissue, both in malignancies of
gastrointestinal tract or outside the gut, has been found, and these bacteria seem able to modulate
response both to chemotherapy and immunotherapy [7,42–46]. Actually, Fusobacterium nucleatum,
which has been detected both in primary colorectal cancer and relative liver metastases, is associated
with a worse prognosis compared to germ-free tumors [47]. Similarly, in pancreatic cancer, a large
bacterial population suppresses monocytic differentiation, thus inducing T-cell anergy and interfering
with response to gemcitabine [48].
Furthermore, the microbiota has been implicated in response to several chemotherapies,
like 5-fluorouracil, cyclophosphamide, irinotecan, oxaliplatin, gemcitabine, and methotrexate [49–55].
3. Microbiota and Prostate Cancer
Prostate cancer is the second leading cause of death and the first type of cancer for incidence in
the male population [9]. Its pathogenesis and natural history are strongly linked to its dependence on
androgen hormones, but the discovery of other risk factors that may participate in cancer development,
progression, or resistance to therapies is of particular interest. Risk factors evaluated for their potential
implication in the etiology of prostate cancer are viral and bacterial infections, inflammatory stimuli,
and environmental factors, like diet and lifestyle [56–58].
The evidence available in the literature is pointing out that the human microbiome residing
in multiple anatomic sites, such as urinary tract, gastrointestinal tract, and oral cavity, may play
an important role in prostate health and diseases like prostatitis, chronic pelvic pain syndrome, benign
prostatic hyperplasia, and prostate cancer [59].
The association between infectious disease, inflammation, and cancer has been widely studied
in many malignancies. There is increasing knowledge about the role of the microbiota in promoting
the status of chronic inflammation and its possible implication in prostate cancer development [60].
The discovery of a urinary microbiome composed of many different microorganisms supports this
hypothesis because the prostate is exposed to many inflammatory stimuli deriving from the bacteria of
this environment. In fact, the anatomy of the prostate, which is in close proximity with the urethra,
exposes this organ to the microorganism residing in the urinary tract. Shrestha and colleagues recently
carried out a study on urine samples from men prior to undergoing prostate biopsy in order to
determine whether the urinary microbiome could be associated with the presence of cancer, cancer
grade, and the type and degree of prostate inflammation [23]. The study demonstrated that men
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with biopsy-proven prostate cancer presented a higher proportion of a cluster of bacteria frequently
associated with urogenital infections, like prostatitis, bacterial vaginosis, and urinary tract infections,
than biopsy-negative samples. This cluster was characterized by Streptococcus anginosus, Anaerococcus
lactolyticus, Anaerococcus obesiensis, Actinobaculum schaalii, Varibaculum cambriense, and Propionimicrobium
lymphophilum. Of note, some species were differently represented in the presence or absence of acute
inflammation or in high- versus low-grade cancers.
Moreover, inflammation has been associated with development of prostate cancer though other
different putative mechanisms [60]. Prostate inflammation, which is very common in adult men,
is characterized by an increased number of inflammatory cells into the prostate tissue that have
been hypothesized to be correlated with cancer development and progression [57,61]. For example,
strong tumor infiltrating lymphocytes expression has been associated with short PSA-free survival
in patients with local prostate carcinoma treated with prostatectomy [62]. Furthermore, it has been
speculated that inflammation could promote cancer development through the release of reactive
oxygen species (ROS) and reactive nitrogen species by immune cells that could directly damage DNA
and cause genetic instability [57]. The oxidative stress and the consequent cellular damage and death
are supposed to stimulate proliferation of atrophic luminal epithelial cells that create the regions
known as proliferative inflammatory atrophy (PIA), characterized by areas of glandular atrophy and
epithelial cell proliferation associated with chronic inflammation [63]. PIA is a regenerative lesion
characterized by elevated Bcl-2 expression and consequent low apoptotic rate [63]. These lesions
have been identified as precursors of prostate malignancies as they have been observed in direct
morphological transition with high-grade prostate intraepithelial neoplasia (PIN), a pre-neoplastic
lesion, and even with adenocarcinoma [63–65].
Chronic inflammation is known to be associated with development of multiple types of cancer:
among the mechanisms behind this process there is the production of reactive chemical compounds,
like superoxide, hydrogen peroxide, and nitric oxide released from cells of the immune system
activated during chronic inflammation, which cause oxidative and nitrosative damage to DNA in the
epithelial cells [66]. This process produces cell death and stimulates regeneration of epithelial cells
exposed to DNA-damaging agents, thus resulting in an increased risk of mutation [57].
The main causes of prostate inflammation are infections like bacterial prostatitis frequently linked
to E. Coli or other species of Enterobacteriaceae [67], hormonal alterations such as estrogen exposure that
could cause architectural alterations, physical trauma consequent to corpora amylacea, urine reflux,
and diets rich in carcinogens that can reach the prostate and cause DNA damage [57]. The connection
between inflammation and prostate cancer development stages is represented in Figure 1.
In a pathological state, for example, prostate infection or physical trauma due to corpora amylacea
or urine reflux, the outgrowth of pathogenic bacteria and the breach of the epithelial barrier can induce
an inflammatory state, characterized by an infiltration of immune cells (macrophages, neutrophils,
and lymphocytes), which release reactive oxygen species (ROS), reactive nitrogen species, and
pro-inflammatory cytokines, causing DNA damage, cell injury, and cell death. The resulting chronic
inflammation state stimulates epithelial cell regeneration, creating primarily the regions known as
proliferative inflammatory atrophy (PIA), which further evolve into low-grade and high-grade prostate
intraepithelial neoplasia (PIN) and, finally, into prostate adenocarcinoma.
Liss et al. analyzed using 16S rRNA amplicon sequencing the rectal microbiome profile from
rectal swab of patients undergoing transrectal prostate biopsy. No differences were found among
men diagnosed with and without prostate cancer, except for an enrichment of the proinflammatory
species Bacteroides and Streptococcus in patients with prostate cancer [68]. Furthermore, the authors
tried to identify a possible microbiome profile that could predict prostate cancer risk on the basis of ten
aberrant metabolic pathways. They reported that bacteria associated with carbohydrate metabolism
pathways were in abundance in patients with prostate cancer, whereas bacteria associated with folate,
biotin, and riboflavin were less abundant. Even though the search for specific microbiome profiles
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with diagnostic value is undoubtedly interesting, it may be too soon to accomplish this task based on
the available data, and larger metatranscriptomic and metabolomics studies are warranted [69].
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The microbial ecosystem of tumoral, peritumoral, and non-tumoral prostate tissue collected
after radical prostatectomy has been analyzed through massive ultradeep pyrosequencing. In all
types of samples, the dominant phylum was Actinobacteria, of which the most abundant genera
were Propionibacterium in all the three different tissues, followed by Firmicutes and Proteobacteria;
Staphylococcus spp. were more represented in the tumor and peri-tumor tissues [70].
With regards to the role of gastrointestinal microbiome in cancer treatment response, the evidence
on this connection in prostate cancer incomplete, unlike other types of tumors, as previously
reported. Sfanos and colleagues profiled the fecal microbiota of 30 subjects using 16S rDNA amplicon
sequencing, including healthy male volunteers and men with localized, biochemically recurrent, and
metastatic prostate cancer [71]. The results showed a greater abundance of Akkermansia muciniphila and
Ruminococcaceae spp. in the gastrointestinal microbiota of men being treated with oral androgen receptor
axis-targeted therapies such as bicalutamide, enzalutamide, and abiraterone acetate. These species
are also linked to response to anti-PD-1 immunotherapy [43,44,72,73]. Immune checkpoint inhibitors
are currently under evaluation in patients with prostate cancer [74]; thus, the connection between the
microbiota and the response to these therapies is an interesting area of research in order to identify
putative modulating factors of efficacy of immunotherapy. Furthermore, in the study by Sfanos et
al., the microbiota composition of men being treated with anti-androgens was different than the
one of men treated only with gonadotropin-releasing hormone agonists/antagonists or not being
treated, since it was enriched with functional pathways involving steroid biosynthesis [71]. The authors
speculate that there could be a deep connection between microbiota and steroidogenesis, in particular,
that species of bacteria capable of steroid biosynthesis could create different pathways of androgen
production, thus interfering with the response to anti-androgen therapies. The interaction between
bacteria and steroidogenesis has been previously investigated, and there is evidence that some bacteria
are able to metabolize and catabolize estrogen and androgen precursors, thus affecting their systemic
levels [75,76]. There is further evidence in support of the connection between the gut microbiota and
hormones: the gut microbiota produces, secretes, and regulates levels of hormones, affecting host
metabolism, immunity, and behavior [77]. This relationship, though, seems to be bidirectional as
the microbiota is itself affected by host’s hormones: in fact, host’s factors like diet, exercise, mood,
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general health state, stress, and gender can alter hormonal levels, which can produce an alteration
in the microbiota in terms of bacterial growth or increased or decreased virulence [77]. Furthermore,
studies on animal models suggest that the gastrointestinal microbiota may be affected also by androgen
deficiency as in a castration state: there is evidence showing an increased Firmicutes/Bacteroidetes
ratio and Lactobacillus species in the feces of high-fat diet-fed castrated mice, and this alteration in the
microbiota composition was associated with abdominal obesity [78]. This intricate connection between
microbiota and hormones is of particular interest, especially regarding those cancers deeply influenced
by hormones levels, such as prostate cancer, that recognize androgen hormones as the main factor
guiding its development, treatment, and resistance to therapies [79]. Moreover, there is evidence of the
involvement of the microbiome also in breast cancer, another type of tumor strongly dependent on
hormones, especially through the interaction of the microbiome and estrogen metabolism [80].
The studies investigating the connection between microbiota and prostate cancer previously
discussed are summarized in Table 1.
Table 1. Studies discussed in the manuscript investigating the connection between microbiota and
prostate cancer.
Reference Samples Findings Bacteria
Shrestha E et al.
J. Urol. 2018
[23]
Urine samples from men
prior to undergoing
prostate biopsy
Men with biopsy proven prostate
cancer presented a higher proportion
of a cluster of bacteria frequently
associated with urogenital infections,
like prostatitis, bacterial vaginosis,
and urinary tract infections
Streptococcus anginosus,
Anaerococcus lactolyticus,
Anaerococcus obesiensis,
Actinobaculum schaalii,
Varibaculum cambriense,
Propionimicrobium
lymphophilum
Liss MA et al.
Eur. Urol. 2018
[68]
Rectal swab of patients
undergoing transrectal
prostate biopsy
Enrichment of the proinflammatory
species Bacteroides and Streptococcus in
patients with prostate cancer. Bacteria
associated with carbohydrate
metabolism pathways were in
abundance in patients with prostate
cancer, whereas bacteria associated
with folate, biotin, and riboflavin
were less abundant.
Bacteroides, Streptococcus
Cavarretta I et al.
Eur. Urol. 2017
[70]
Tumoral, peritumoral,
and non-tumoral
prostate tissue collected
after radical
prostatectomy
In all types of samples, the dominant
phylum was Actinobacteria (most
abundant genera: Propionibacterium),
followed by Firmicutes and
Proteobacteria; Staphylococcus spp.
were more represented in the tumor
and peri-tumor tissues.
Actinobacteria, Firmicutes,
Proteobacteria
Sfanos KS et al.
Prostate Cancer
and Prostatic
Diseases 2018
[71]
Fecal samples of healthy
male volunteers and men
with localized,
biochemically recurrent
and metastatic prostate
cancer
Greater abundance of Akkermansia
muciniphila and Ruminococcaceae spp.
in the gastrointestinal microbiota of
men on treatment with oral androgen
receptor axis-targeted therapies such
as bicalutamide, enzalutamide, and
abiraterone acetate
Akkermansia muciniphila,
Ruminococcaceae spp
4. Conclusions
The deep interaction of the human microbiota and its host seems to be fundamental in maintaining
a balance that, if altered, could lead to many diseases. The knowledge of the mechanisms underlying
cancer development or the instauration of resistance to therapies is essential in order to overcome
them. The bacteria resident in the human body seem to influence many steps of the natural history
of cancers.
The microbiota and its environment live in an in intertwined relationship, and the challenge seems
to be to understand which is the first to influence the other. With the increasing evidence available,
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it can be speculated that, while on one hand the microbiota could be a promoter in the development
or progression of cancer, on the other hand it also seems possible that cancer itself could change the
microenvironment, thus causing changes in the microbiota composition. Moreover, the microbiota is
a double-sided element for its host: friend when in balance and foe if a state of dysbiosis occurs. It can
also modulate drug activity, acting as a sort of pharmacist inside our body.
In prostate cancer, the role of the microbiota is still not well understood, but increasing evidence
supports its putative role in health and disease of the prostate. The scarce and still mostly speculative
nature of the body of work investigating the association of microbiome and prostate cancer requires
a deeper understanding of this subject through more extensive studies on the possible implications of
the microbiota in various aspects of prostate cancer.
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